RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Jorge Duconge to Xenograft Model Antitumor Assays

Back to Details
This is a "connection" page, showing publications Jorge Duconge has written about Xenograft Model Antitumor Assays.
Jorge Duconge
Connection Strength
0.257
Xenograft Model Antitumor Assays
  1. Duconge J, Fern?ndez-S?nchez E, Mac?as A, Castillo R, Garcia I, Beausoleil I, Amador JF, Matheu J. Monoclonal anti-EGFreceptor antibody (ior-R3) pharmacokinetic study in tumor bearing nude mice: role of the receptor-mediated endocytosis on drug clearance. Eur J Drug Metab Pharmacokinet. 2002 Apr-Jun; 27(2):101-5.
    View in: PubMed
    Score: 0.201
  2. Duconge J, Castillo R, Crombet T, Alvarez D, Matheu J, Vecino G, Alonso K, Beausoleil I, Valenzuela C, Becquer MA, Fern?ndez-S?nchez E. Integrated pharmacokinetic-pharmacodynamic modeling and allometric scaling for optimizing the dosage regimen of the monoclonal ior EGF/r3 antibody. Eur J Pharm Sci. 2004 Feb; 21(2-3):261-70.
    View in: PubMed
    Score: 0.057
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support